Effects of frequently prescribed antiseizure medications on motor vehicle driving performance: Narrative review based on a tiered approach for the assessment of clinically meaningful driving impairment in the Ministry of Health, Labour, and Welfare guideline
- PMID: 39497515
- PMCID: PMC11609745
- DOI: 10.1002/npr2.12469
Effects of frequently prescribed antiseizure medications on motor vehicle driving performance: Narrative review based on a tiered approach for the assessment of clinically meaningful driving impairment in the Ministry of Health, Labour, and Welfare guideline
Abstract
Patients with epilepsy often require long-term treatment with antiseizure medications, and their impact on daily activities, particularly driving, is of significant concern. The recently published "Guideline for Evaluating Effects of Psychotropic Drugs on the Performance to Drive a Motor Vehicle" in Japan provides a framework that can be referred to for not only the evaluation of new drugs but also the reevaluation of approved drugs. This study conducted a literature review regarding the effects of carbamazepine, valproate, lamotrigine, lacosamide, and levetiracetam, which are frequently prescribed for epilepsy, on driving performance following the guideline's tiered evaluation approach. Analyses of pharmacological, pharmacodynamic, and adverse events suggested that these drugs primarily affect arousal function. Driving studies showed that acute administration of carbamazepine, but not chronic monotherapy with carbamazepine, valproate, lamotrigine, and levetiracetam, significantly impairs driving performance. Epidemiological studies have not identified a definitive association between these drugs and traffic accidents. Initial administration of these five antiseizure medications may affect driving performance, warranting special attention, but the influence appears to diminish with continued use. Nevertheless, while long-term administration of these five drugs may not have a clinically meaningful effect on driving performance, safe driving is not guaranteed for each individual patient, and appropriate individualized guidance is important in clinical practice.
Keywords: antiseizure medication; driving performance; drug evaluation; guideline; traffic accident.
© 2024 The Author(s). Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
Conflict of interest statement
KI has received speakers' honoraria from Eisai, Kyowa, Meiji Seika Pharma, MSD, Otsuka, Sumitomo Pharma, Takeda, Towa, and Viatris, outside the submitted work. RY has received speakers' honoraria from Sumitomo Pharma, Eisai, Otsuka, and Viatris, outside the submitted work. KK has received speaker's honoraria from Eisai, Daiichi‐Sankyo, Otsuka, and UCB pharmaceutical companies, outside the submitted work. MA has received subsidies from Kyowa Kirin. NO has received research support or speakers' honoraria from, or has served as a joint researcher with, or a consultant to, Sumitomo Pharma, Otsuka, Viatris, Eisai, Mochida, Kyowa Pharmaceutical Industry, Nihon Medi‐Physics, Nippon Chemiphar, Medical Review, Nippon Boehringer Ingelheim, and SUSMED, outside the submitted work. The other authors have no conflicts of interest to declare. Board member is coauthor: R. Yoshimura is an editorial board member of
The views expressed in this article are those of the authors and do not necessarily reflect the official views of the Pharmaceuticals and Medical Devices Agency.
Figures
Similar articles
-
The new guideline for evaluating effects of psychotropic drugs on the performance to drive a motor vehicle in Japan: Comparison with US FDA guideline.Neuropsychopharmacol Rep. 2023 Jun;43(2):172-176. doi: 10.1002/npr2.12339. Epub 2023 Apr 14. Neuropsychopharmacol Rep. 2023. PMID: 37057649 Free PMC article. Review.
-
Trends in antiseizure medication prescription patterns among all adults, women, and older adults with epilepsy: A German longitudinal analysis from 2008 to 2020.Epilepsy Behav. 2022 May;130:108666. doi: 10.1016/j.yebeh.2022.108666. Epub 2022 Mar 25. Epilepsy Behav. 2022. PMID: 35339390
-
Antiseizure medication treatment pathways for US Medicare beneficiaries with newly treated epilepsy.Epilepsia. 2022 Jun;63(6):1571-1579. doi: 10.1111/epi.17226. Epub 2022 Mar 25. Epilepsia. 2022. PMID: 35294775 Free PMC article.
-
Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study.JAMA Neurol. 2022 Apr 1;79(4):370-379. doi: 10.1001/jamaneurol.2021.5487. JAMA Neurol. 2022. PMID: 35157004 Free PMC article.
-
Epilepsy treatment in adults and adolescents: Expert opinion, 2016.Epilepsy Behav. 2017 Apr;69:186-222. doi: 10.1016/j.yebeh.2016.11.018. Epub 2017 Feb 23. Epilepsy Behav. 2017. PMID: 28237319 Review.
References
-
- Nakabayashi T, Iwamoto K, Yamaguchi A, Konishi Y, Saji M, Yoshimura R, et al. Guideline for evaluating the effects of psychotropic drugs on motor vehicle driving performance in Japan: a tiered approach for the assessment of clinically meaningful driving impairment. Neuropsychopharmacol Rep. 2024;44:308–313. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical